Distinct precursor landscape of subcutaneous and visceral fat in development and aging
Lin F., Sul HS.
Narrative Review, published in Cell Rep (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Cell Rep (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41420858
- PMCID
- PMC12883077
- DOI
- 10.1016/j.celrep.2025.116706
- Citations
- 1
Abstract (original English)
White adipose tissue (WAT) is the primary energy storage organ and can be categorized mainly into subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT). Although all WAT accumulates triglycerides to store excess energy, VAT is associated with pathological conditions, whereas SAT is considered beneficial for metabolic health. In fact, SAT and VAT are from distinct developmental origins. Moreover, within these depots, there is heterogeneity in developmental origin and in adipose precursor population. In various conditions, such as obesity and aging, adipose tissue undergoes distinct changes. In aging, pathogenic VAT tends to increase, whereas protective peripheral SAT is known to be reduced significantly, but the mechanism driving this depot-specific reduction in SAT is not well understood. Here, we review recent research on depot-specific adipose precursor heterogeneity in SAT and VAT and new and distinct adipose precursor populations arising in SAT and VAT during aging to bring differential changes in adipose mass.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.